Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2
Identifieur interne : 00C513 ( Main/Exploration ); précédent : 00C512; suivant : 00C514Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2
Auteurs : P. Brooks ; P. Emery [Royaume-Uni] ; J. F. Evans ; H. Fenner ; C. J. Hawkey ; C. Patrono ; J. Smolen ; F. Breedveld ; R. Day ; M. Dougados ; E. W. Ehrich ; J. Gijon-Ban Os ; T. K. Kvien ; M. H. Van Rijswijk ; T. Warner [Royaume-Uni] ; H. Zeidler [Allemagne]Source :
- Rheumatology [ 1462-0324 ] ; 1999-08.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme, Pharmacologie.
English descriptors
- KwdEn :
- Acad, Active site, Acute pain, Adverse events, Amino acids, Arachidonic, Arachidonic acid, Arachidonic acid metabolism, Arthritis, Arthritis rheum, Aspirin, Assay, Assay system, Assay systems, Available nsaids variably, Biochim biophys acta, Biol, Biol chem, Blood samples, COX-1, COX-2-specific inhibition, COX-2/COX-1 ratios, Celecoxib, Chem, Chemotherapy, Clin, Clin pharmacol, Clinical implications, Clinical studies, Clinical trials, Congestive heart failure, Cyclooxygenase, Dental pain studies, Dos, Dose range, Drug concentrations, Drug safety, Endogenous substrate, Endoperoxide, Endoscopic study, Endothelial cells, Enzymatic domain, Gastric, Gastric mucosa, Gastrointestinal safety, Gastrointestinal tolerability, Healthy volunteers, Human, Human assay, Human assay system, Human platelets, Ibuprofen, Icmmac meeting, In vitro, In vivo, Inducible, Inhibition, Inhibitor, Inhibitor binding site, Isoforms, Isozyme, Mechanism of action, Meloxicam, Molecular form, Mrna, NSAIDs, Natl, Non steroidal antiinflammatory agent, Nonsteroidal, Nonsteroidal drugs, Nsaid, Nsaid gastropathy, Osteoarthritis, Pharmacol, Pharmacology, Placebo, Plasma proteins, Platelet, Platelet aggregation, Platelet function, Proc, Proc natl acad, Prostaglandin, Prostaglandin endoperoxide synthase, Prostaglandin production, Prostaglandin-endoperoxide synthase, Recombinant enzymes, Relative inhibition, Rescue medication, Rheum, Rheumatoid arthritis, Rheumatol, Rheumatology, Rofecoxib, Selective inhibition, Selective inhibitor, Selectivity, Single dose, Specificity, Supratherapeutic doses, Synovial, Synovial tissue, Synthase, Therapeutic dose range, Therapeutic dose ranges, Therapeutic doses, Therapeutic implications, Tracheal epithelial cells, Treatment, Ulcer complications, University hospital, Vivo administration, Vivo assays, Whole cells.
- Teeft :
- Acad, Active site, Adverse events, Amino acids, Arachidonic, Arachidonic acid, Arachidonic acid metabolism, Arthritis, Arthritis rheum, Aspirin, Assay, Assay system, Assay systems, Available nsaids variably, Biochim biophys acta, Biol, Biol chem, Blood samples, Celecoxib, Chem, Clin, Clin pharmacol, Clinical implications, Clinical studies, Clinical trials, Congestive heart failure, Cyclooxygenase, Dental pain studies, Dos, Dose range, Drug concentrations, Drug safety, Endogenous substrate, Endoperoxide, Endoscopic study, Endothelial cells, Enzymatic domain, Gastric, Gastric mucosa, Gastrointestinal tolerability, Healthy volunteers, Human assay, Human assay system, Human platelets, Ibuprofen, Icmmac meeting, Inducible, Inhibition, Inhibitor, Inhibitor binding site, Isoforms, Meloxicam, Mrna, Natl, Nonsteroidal, Nonsteroidal drugs, Nsaid, Nsaid gastropathy, Pharmacol, Placebo, Plasma proteins, Platelet, Platelet aggregation, Platelet function, Proc, Proc natl acad, Prostaglandin, Prostaglandin endoperoxide synthase, Prostaglandin production, Recombinant enzymes, Relative inhibition, Rescue medication, Rheum, Rheumatoid arthritis, Rheumatol, Rheumatology, Rofecoxib, Selective inhibition, Selective inhibitor, Selectivity, Single dose, Supratherapeutic doses, Synovial, Synovial tissue, Synthase, Therapeutic dose range, Therapeutic dose ranges, Therapeutic doses, Therapeutic implications, Tracheal epithelial cells, Ulcer complications, University hospital, Vivo administration, Vivo assays, Whole cells.
Abstract
The International Consensus Meeting on the Mode of Action of COX-2 Inhibition (ICMMAC) brought together 17 international experts in arthritis, gastroenterology and pharmacology on 5–6 December 1997. The meeting was convened to provide a definition of COX-2 specificity and to consider the clinical relevance of COX-2-specific agents. These compounds are a new class of drugs that specifically inhibit the enzyme COX-2 while having no effect on COX-1 across the whole therapeutic dose range. The objectives of the meeting were to review the currently available data regarding the roles and biology of COX-1 and COX-2, and to foster a consensus definition on COX-2 specificity. At the present time, no guidelines exist for the in vitro and in vivo assessment of COX specificity, and it was felt that consensus discussion might clarify some of these issues. The meeting also reviewed recent clinical data on COX-2-specific inhibitors. The following article reflects discussion at this meeting and provides a consensus definition of COX-2-specific inhibitors.
Url:
DOI: 10.1093/rheumatology/38.8.779
Affiliations:
- Allemagne, Royaume-Uni
- Angleterre, Grand Londres, Yorkshire-et-Humber
- Leeds, Londres
- Université de Leeds
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000804
- to stream Istex, to step Curation: 000804
- to stream Istex, to step Checkpoint: 002176
- to stream Main, to step Merge: 00D486
- to stream PascalFrancis, to step Corpus: 006229
- to stream PascalFrancis, to step Curation: 006E25
- to stream PascalFrancis, to step Checkpoint: 006005
- to stream Main, to step Merge: 00D718
- to stream Main, to step Curation: 00C513
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2</title><author><name sortKey="Brooks, P" sort="Brooks, P" uniqKey="Brooks P" first="P." last="Brooks">P. Brooks</name></author><author><name sortKey="Emery, P" sort="Emery, P" uniqKey="Emery P" first="P." last="Emery">P. Emery</name></author><author><name sortKey="Evans, J F" sort="Evans, J F" uniqKey="Evans J" first="J. F." last="Evans">J. F. Evans</name></author><author><name sortKey="Fenner, H" sort="Fenner, H" uniqKey="Fenner H" first="H." last="Fenner">H. Fenner</name></author><author><name sortKey="Hawkey, C J" sort="Hawkey, C J" uniqKey="Hawkey C" first="C. J." last="Hawkey">C. J. Hawkey</name></author><author><name sortKey="Patrono, C" sort="Patrono, C" uniqKey="Patrono C" first="C." last="Patrono">C. Patrono</name></author><author><name sortKey="Smolen, J" sort="Smolen, J" uniqKey="Smolen J" first="J." last="Smolen">J. Smolen</name></author><author><name sortKey="Breedveld, F" sort="Breedveld, F" uniqKey="Breedveld F" first="F." last="Breedveld">F. Breedveld</name></author><author><name sortKey="Day, R" sort="Day, R" uniqKey="Day R" first="R." last="Day">R. Day</name></author><author><name sortKey="Dougados, M" sort="Dougados, M" uniqKey="Dougados M" first="M." last="Dougados">M. Dougados</name></author><author><name sortKey="Ehrich, E W" sort="Ehrich, E W" uniqKey="Ehrich E" first="E. W." last="Ehrich">E. W. Ehrich</name></author><author><name sortKey="Gijon Ban Os, J" sort="Gijon Ban Os, J" uniqKey="Gijon Ban Os J" first="J." last="Gijon-Ban Os">J. Gijon-Ban Os</name></author><author><name sortKey="Kvien, T K" sort="Kvien, T K" uniqKey="Kvien T" first="T. K." last="Kvien">T. K. Kvien</name></author><author><name sortKey="Van Rijswijk, M H" sort="Van Rijswijk, M H" uniqKey="Van Rijswijk M" first="M. H." last="Van Rijswijk">M. H. Van Rijswijk</name></author><author><name sortKey="Warner, T" sort="Warner, T" uniqKey="Warner T" first="T." last="Warner">T. Warner</name></author><author><name sortKey="Zeidler, H" sort="Zeidler, H" uniqKey="Zeidler H" first="H." last="Zeidler">H. Zeidler</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:29B54ACFB2ECA204ADD1BD689D6AB2709C160918</idno><date when="1999" year="1999">1999</date><idno type="doi">10.1093/rheumatology/38.8.779</idno><idno type="url">https://api.istex.fr/document/29B54ACFB2ECA204ADD1BD689D6AB2709C160918/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000804</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000804</idno><idno type="wicri:Area/Istex/Curation">000804</idno><idno type="wicri:Area/Istex/Checkpoint">002176</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">002176</idno><idno type="wicri:doubleKey">1462-0324:1999:Brooks P:interpreting:the:clinical</idno><idno type="wicri:Area/Main/Merge">00D486</idno><idno type="wicri:source">INIST</idno><idno type="RBID">Pascal:99-0464747</idno><idno type="wicri:Area/PascalFrancis/Corpus">006229</idno><idno type="wicri:Area/PascalFrancis/Curation">006E25</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">006005</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">006005</idno><idno type="wicri:doubleKey">1462-0324:1999:Brooks P:interpreting:the:clinical</idno><idno type="wicri:Area/Main/Merge">00D718</idno><idno type="wicri:Area/Main/Curation">00C513</idno><idno type="wicri:Area/Main/Exploration">00C513</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2</title><author><name sortKey="Brooks, P" sort="Brooks, P" uniqKey="Brooks P" first="P." last="Brooks">P. Brooks</name></author><author><name sortKey="Emery, P" sort="Emery, P" uniqKey="Emery P" first="P." last="Emery">P. Emery</name><affiliation wicri:level="4"><orgName type="university">Université de Leeds</orgName><country>Royaume-Uni</country><placeName><settlement type="city">Leeds</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Yorkshire-et-Humber</region></placeName></affiliation></author><author><name sortKey="Evans, J F" sort="Evans, J F" uniqKey="Evans J" first="J. F." last="Evans">J. F. Evans</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Fenner, H" sort="Fenner, H" uniqKey="Fenner H" first="H." last="Fenner">H. Fenner</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Hawkey, C J" sort="Hawkey, C J" uniqKey="Hawkey C" first="C. J." last="Hawkey">C. J. Hawkey</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Patrono, C" sort="Patrono, C" uniqKey="Patrono C" first="C." last="Patrono">C. Patrono</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Smolen, J" sort="Smolen, J" uniqKey="Smolen J" first="J." last="Smolen">J. Smolen</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Breedveld, F" sort="Breedveld, F" uniqKey="Breedveld F" first="F." last="Breedveld">F. Breedveld</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Day, R" sort="Day, R" uniqKey="Day R" first="R." last="Day">R. Day</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Dougados, M" sort="Dougados, M" uniqKey="Dougados M" first="M." last="Dougados">M. Dougados</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Ehrich, E W" sort="Ehrich, E W" uniqKey="Ehrich E" first="E. W." last="Ehrich">E. W. Ehrich</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Gijon Ban Os, J" sort="Gijon Ban Os, J" uniqKey="Gijon Ban Os J" first="J." last="Gijon-Ban Os">J. Gijon-Ban Os</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Kvien, T K" sort="Kvien, T K" uniqKey="Kvien T" first="T. K." last="Kvien">T. K. Kvien</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Van Rijswijk, M H" sort="Van Rijswijk, M H" uniqKey="Van Rijswijk M" first="M. H." last="Van Rijswijk">M. H. Van Rijswijk</name><affiliation><wicri:noCountry code="subField"></wicri:noCountry></affiliation></author><author><name sortKey="Warner, T" sort="Warner, T" uniqKey="Warner T" first="T." last="Warner">T. Warner</name><affiliation wicri:level="3"><country>Royaume-Uni</country><wicri:regionArea>Vascular Inflammation, The William Harvey Research Institute, St Bartholomew's & The Royal London School of Medicine and Dentistry, London</wicri:regionArea><placeName><settlement type="city">Londres</settlement><region type="country">Angleterre</region><region type="région" nuts="1">Grand Londres</region></placeName></affiliation></author><author><name sortKey="Zeidler, H" sort="Zeidler, H" uniqKey="Zeidler H" first="H." last="Zeidler">H. Zeidler</name><affiliation wicri:level="1"><country xml:lang="fr">Allemagne</country><wicri:regionArea>Department of Internal Medicine and Rheumatology, Medizinische Hochschule Hanover</wicri:regionArea><wicri:noRegion>Medizinische Hochschule Hanover</wicri:noRegion><wicri:noRegion>Medizinische Hochschule Hanover</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Rheumatology</title><title level="j" type="abbrev">Rheumatology</title><idno type="ISSN">1462-0324</idno><idno type="eISSN">1462-0332</idno><imprint><publisher>Oxford University Press</publisher><date type="published" when="1999-08">1999-08</date><biblScope unit="volume">38</biblScope><biblScope unit="issue">8</biblScope><biblScope unit="page" from="779">779</biblScope><biblScope unit="page" to="788">788</biblScope></imprint><idno type="ISSN">1462-0324</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1462-0324</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Acad</term><term>Active site</term><term>Acute pain</term><term>Adverse events</term><term>Amino acids</term><term>Arachidonic</term><term>Arachidonic acid</term><term>Arachidonic acid metabolism</term><term>Arthritis</term><term>Arthritis rheum</term><term>Aspirin</term><term>Assay</term><term>Assay system</term><term>Assay systems</term><term>Available nsaids variably</term><term>Biochim biophys acta</term><term>Biol</term><term>Biol chem</term><term>Blood samples</term><term>COX-1</term><term>COX-2-specific inhibition</term><term>COX-2/COX-1 ratios</term><term>Celecoxib</term><term>Chem</term><term>Chemotherapy</term><term>Clin</term><term>Clin pharmacol</term><term>Clinical implications</term><term>Clinical studies</term><term>Clinical trials</term><term>Congestive heart failure</term><term>Cyclooxygenase</term><term>Dental pain studies</term><term>Dos</term><term>Dose range</term><term>Drug concentrations</term><term>Drug safety</term><term>Endogenous substrate</term><term>Endoperoxide</term><term>Endoscopic study</term><term>Endothelial cells</term><term>Enzymatic domain</term><term>Gastric</term><term>Gastric mucosa</term><term>Gastrointestinal safety</term><term>Gastrointestinal tolerability</term><term>Healthy volunteers</term><term>Human</term><term>Human assay</term><term>Human assay system</term><term>Human platelets</term><term>Ibuprofen</term><term>Icmmac meeting</term><term>In vitro</term><term>In vivo</term><term>Inducible</term><term>Inhibition</term><term>Inhibitor</term><term>Inhibitor binding site</term><term>Isoforms</term><term>Isozyme</term><term>Mechanism of action</term><term>Meloxicam</term><term>Molecular form</term><term>Mrna</term><term>NSAIDs</term><term>Natl</term><term>Non steroidal antiinflammatory agent</term><term>Nonsteroidal</term><term>Nonsteroidal drugs</term><term>Nsaid</term><term>Nsaid gastropathy</term><term>Osteoarthritis</term><term>Pharmacol</term><term>Pharmacology</term><term>Placebo</term><term>Plasma proteins</term><term>Platelet</term><term>Platelet aggregation</term><term>Platelet function</term><term>Proc</term><term>Proc natl acad</term><term>Prostaglandin</term><term>Prostaglandin endoperoxide synthase</term><term>Prostaglandin production</term><term>Prostaglandin-endoperoxide synthase</term><term>Recombinant enzymes</term><term>Relative inhibition</term><term>Rescue medication</term><term>Rheum</term><term>Rheumatoid arthritis</term><term>Rheumatol</term><term>Rheumatology</term><term>Rofecoxib</term><term>Selective inhibition</term><term>Selective inhibitor</term><term>Selectivity</term><term>Single dose</term><term>Specificity</term><term>Supratherapeutic doses</term><term>Synovial</term><term>Synovial tissue</term><term>Synthase</term><term>Therapeutic dose range</term><term>Therapeutic dose ranges</term><term>Therapeutic doses</term><term>Therapeutic implications</term><term>Tracheal epithelial cells</term><term>Treatment</term><term>Ulcer complications</term><term>University hospital</term><term>Vivo administration</term><term>Vivo assays</term><term>Whole cells</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Antiinflammatoire non stéroïde</term><term>Chimiothérapie</term><term>Forme moléculaire</term><term>Homme</term><term>In vitro</term><term>In vivo</term><term>Isozyme</term><term>Mécanisme action</term><term>Pharmacologie</term><term>Prostaglandin-endoperoxide synthase</term><term>Spécificité</term><term>Traitement</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Acad</term><term>Active site</term><term>Adverse events</term><term>Amino acids</term><term>Arachidonic</term><term>Arachidonic acid</term><term>Arachidonic acid metabolism</term><term>Arthritis</term><term>Arthritis rheum</term><term>Aspirin</term><term>Assay</term><term>Assay system</term><term>Assay systems</term><term>Available nsaids variably</term><term>Biochim biophys acta</term><term>Biol</term><term>Biol chem</term><term>Blood samples</term><term>Celecoxib</term><term>Chem</term><term>Clin</term><term>Clin pharmacol</term><term>Clinical implications</term><term>Clinical studies</term><term>Clinical trials</term><term>Congestive heart failure</term><term>Cyclooxygenase</term><term>Dental pain studies</term><term>Dos</term><term>Dose range</term><term>Drug concentrations</term><term>Drug safety</term><term>Endogenous substrate</term><term>Endoperoxide</term><term>Endoscopic study</term><term>Endothelial cells</term><term>Enzymatic domain</term><term>Gastric</term><term>Gastric mucosa</term><term>Gastrointestinal tolerability</term><term>Healthy volunteers</term><term>Human assay</term><term>Human assay system</term><term>Human platelets</term><term>Ibuprofen</term><term>Icmmac meeting</term><term>Inducible</term><term>Inhibition</term><term>Inhibitor</term><term>Inhibitor binding site</term><term>Isoforms</term><term>Meloxicam</term><term>Mrna</term><term>Natl</term><term>Nonsteroidal</term><term>Nonsteroidal drugs</term><term>Nsaid</term><term>Nsaid gastropathy</term><term>Pharmacol</term><term>Placebo</term><term>Plasma proteins</term><term>Platelet</term><term>Platelet aggregation</term><term>Platelet function</term><term>Proc</term><term>Proc natl acad</term><term>Prostaglandin</term><term>Prostaglandin endoperoxide synthase</term><term>Prostaglandin production</term><term>Recombinant enzymes</term><term>Relative inhibition</term><term>Rescue medication</term><term>Rheum</term><term>Rheumatoid arthritis</term><term>Rheumatol</term><term>Rheumatology</term><term>Rofecoxib</term><term>Selective inhibition</term><term>Selective inhibitor</term><term>Selectivity</term><term>Single dose</term><term>Supratherapeutic doses</term><term>Synovial</term><term>Synovial tissue</term><term>Synthase</term><term>Therapeutic dose range</term><term>Therapeutic dose ranges</term><term>Therapeutic doses</term><term>Therapeutic implications</term><term>Tracheal epithelial cells</term><term>Ulcer complications</term><term>University hospital</term><term>Vivo administration</term><term>Vivo assays</term><term>Whole cells</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term><term>Pharmacologie</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The International Consensus Meeting on the Mode of Action of COX-2 Inhibition (ICMMAC) brought together 17 international experts in arthritis, gastroenterology and pharmacology on 5–6 December 1997. The meeting was convened to provide a definition of COX-2 specificity and to consider the clinical relevance of COX-2-specific agents. These compounds are a new class of drugs that specifically inhibit the enzyme COX-2 while having no effect on COX-1 across the whole therapeutic dose range. The objectives of the meeting were to review the currently available data regarding the roles and biology of COX-1 and COX-2, and to foster a consensus definition on COX-2 specificity. At the present time, no guidelines exist for the in vitro and in vivo assessment of COX specificity, and it was felt that consensus discussion might clarify some of these issues. The meeting also reviewed recent clinical data on COX-2-specific inhibitors. The following article reflects discussion at this meeting and provides a consensus definition of COX-2-specific inhibitors.</div></front></TEI><affiliations><list><country><li>Allemagne</li><li>Royaume-Uni</li></country><region><li>Angleterre</li><li>Grand Londres</li><li>Yorkshire-et-Humber</li></region><settlement><li>Leeds</li><li>Londres</li></settlement><orgName><li>Université de Leeds</li></orgName></list><tree><noCountry><name sortKey="Breedveld, F" sort="Breedveld, F" uniqKey="Breedveld F" first="F." last="Breedveld">F. Breedveld</name><name sortKey="Brooks, P" sort="Brooks, P" uniqKey="Brooks P" first="P." last="Brooks">P. Brooks</name><name sortKey="Day, R" sort="Day, R" uniqKey="Day R" first="R." last="Day">R. Day</name><name sortKey="Dougados, M" sort="Dougados, M" uniqKey="Dougados M" first="M." last="Dougados">M. Dougados</name><name sortKey="Ehrich, E W" sort="Ehrich, E W" uniqKey="Ehrich E" first="E. W." last="Ehrich">E. W. Ehrich</name><name sortKey="Evans, J F" sort="Evans, J F" uniqKey="Evans J" first="J. F." last="Evans">J. F. Evans</name><name sortKey="Fenner, H" sort="Fenner, H" uniqKey="Fenner H" first="H." last="Fenner">H. Fenner</name><name sortKey="Gijon Ban Os, J" sort="Gijon Ban Os, J" uniqKey="Gijon Ban Os J" first="J." last="Gijon-Ban Os">J. Gijon-Ban Os</name><name sortKey="Hawkey, C J" sort="Hawkey, C J" uniqKey="Hawkey C" first="C. J." last="Hawkey">C. J. Hawkey</name><name sortKey="Kvien, T K" sort="Kvien, T K" uniqKey="Kvien T" first="T. K." last="Kvien">T. K. Kvien</name><name sortKey="Patrono, C" sort="Patrono, C" uniqKey="Patrono C" first="C." last="Patrono">C. Patrono</name><name sortKey="Smolen, J" sort="Smolen, J" uniqKey="Smolen J" first="J." last="Smolen">J. Smolen</name><name sortKey="Van Rijswijk, M H" sort="Van Rijswijk, M H" uniqKey="Van Rijswijk M" first="M. H." last="Van Rijswijk">M. H. Van Rijswijk</name></noCountry><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Emery, P" sort="Emery, P" uniqKey="Emery P" first="P." last="Emery">P. Emery</name></region><name sortKey="Warner, T" sort="Warner, T" uniqKey="Warner T" first="T." last="Warner">T. Warner</name></country><country name="Allemagne"><noRegion><name sortKey="Zeidler, H" sort="Zeidler, H" uniqKey="Zeidler H" first="H." last="Zeidler">H. Zeidler</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 00C513 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 00C513 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:29B54ACFB2ECA204ADD1BD689D6AB2709C160918
|texte= Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2
}}
| This area was generated with Dilib version V0.6.33. |  |